RxDoctor Payments DataLook up a doctor →

David Berz, MD

Hematology & Oncology · Los Angeles, CANPI 1437375128

Payments from drug & device makers

$43,325,259in general payments, 2019–2025

Across 7,639 payments — averaging $5671.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$13.9M
  • Beigene, Ltd.$7.2M
  • Daiichi Sankyo Inc.$2.8M
  • Merck$2.7M
  • Boehringer Ingelheim International GmbH$2.4M
  • Incyte Corporation$2.2M
  • plus $12.2M from 54 others
$1,066in research payments, 2019–2025

Across 3 payments — averaging $355.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim659$13,898,069
Beigene, Ltd.1,845$7,157,800
Daiichi Sankyo Inc.1,304$2,823,094
Merck44$2,665,202
Boehringer Ingelheim International GmbH375$2,419,578
Incyte Corporation1,198$2,173,349
AbbVie108$1,448,283
Janssen Research & Development, LLC64$1,445,803
Boehringer Ingelheim Pharma GmbH & Co.kg104$1,296,954
Genentech, Inc.43$1,114,768
Regeneron84$1,091,593
Biontech SE298$923,958
Mirati Therapeutics, Inc.126$819,133
Beone Medicines Ltd.74$653,039
E.r. Squibb & Sons, L.L.C.68$582,816
G1 Therapeutics, Inc.248$497,431
Amgen26$468,142
Beigene USA, Inc.126$408,940
Pfizer93$333,306
Karyopharm Therapeutics Inc.18$243,851
Astrazeneca UK Limited2$214,306
Eli Lilly6$161,369
Jazz Pharmaceuticals Inc.148$145,070
Sun Pharmaceutical Industries Inc.96$104,116
Genentech USA, Inc.58$52,183
Novartis47$34,228
Ascendis Pharma Endocrinology Inc2$33,160
AstraZeneca(2 entities)103$31,623
EMD Serono, Inc.24$28,515
Seagen Inc.5$25,450
Beone Medicines USA, Inc.7$11,097
Pharmacosmos Therapeutics Inc.3$5,782
Takeda Pharmaceuticals U.S.A., Inc.20$3,035
Helsinn Therapeutics (U.S.), Inc.2$2,737
Boehringer Ingelheim Espana S.A.27$2,441
Johnson & Johnson19$584
Eisai Inc.26$411
Kadmon Corporation LLC2$397
Gilead12$328
Astellas Pharma US Inc13$271
Puma Biotechnology, Inc.6$234
Bayer10$217
AVEO Pharmaceuticals, Inc.3$191
Array Biopharma Inc6$186
Regeneron Healthcare Solutions, Inc.8$159
Tempus AI, Inc3$156
Pharmacyclics LLC, An Abbvie Company5$137
Sanofi7$133
Blueprint Medicines Corporation5$124
Dendreon Pharmaceuticals LLC5$117
Teva Pharmaceuticals USA, Inc.6$107
Amneal Pharmaceuticals LLC4$103
GSK4$101
Exelixis Inc.4$96
GE HealthCare1$94
Lilly USA, LLC3$93
Bristol Myers Squibb4$90
ADC Therapeutics America, Inc.3$82
Tersera Therapeutics LLC2$73
Kyowa Kirin, Inc.3$61

How this compares

$43,325,259 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024
$1,528,008
Medicare patients
232
Services billed
49,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →